Please provide your email address to receive an email when new articles are posted on . Percent predicted FEV 1 did not improve after systemic corticosteroid treatment. This treatment was also not ...
– Systemic sclerosis (SSc) is a rare disease that impacts up to 75,000 people in the United States – – Approximately 80% of SSc patients may be affected by interstitial lung disease (ILD), a ...
The FDA has approved Actemra® (tocilizumab; Genentech) subcutaneous injection for slowing the rate of decline in pulmonary function in SSc-ILD. The Food and Drug Administration (FDA) has approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback